OVERVIEW
Immunotherapy has radically transformed the landscape of frontline treatment for advanced non-small cell lung cancer (NSCLC) without actionable mutations. Join us for this live event to hear our expert panel offer privileged insights into evidence-based guidelines for biomarker testing, the latest data pertaining to therapeutic options for NSCLC with high PD-L1 expression, and strategies to address immune-related adverse events. A patient with history of advanced NSCLC will be on the panel to augment these insights with “teaching moments” from his treatment journey.
GOAL STATEMENT
This activity was designed to improve the knowledge and competence of clinicians with respect to biomarker testing, selection of first-line checkpoint inhibitor therapy, and management of immunotherapy-related adverse events in patients with advanced NSCLC.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to: [LIST] [ITEM]Employ evidence-based biomarker testing for patients with NSCLC [ITEM]Select first-line checkpoint inhibitor therapy for patients with NSCLC based on scientific evidence and therapeutic indications [ITEM]Apply evidence-based strategies for the management of immunotherapy-related adverse events in patients with NSCLC
ACCREDITATION STATEMENT
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO]
[bold]For Physicians[/bold] RMEI Medical Education, LLC designates this live activity for a maximum of 1.0 [italic]AMA PRA Category 1 Credit(s)[/italic]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Provided by RMEI Medical Education, LLC.